Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 4/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4970321 | 0.88 | MEN1 (0.50) | MEN1KMT2ATSHRPKMLMNA | |
| SCHEMBL4969562 | 0.86 | TSHR (0.45) | MEN1KMT2ATSHRPKMLMNA | |
| SCHEMBL4970645 | 0.85 | MEN1 (0.57) | MEN1KMT2ATSHRPKMLMNA | |
| SCHEMBL4970662 | 0.82 | MEN1 (0.41) | MEN1KMT2ATSHRPKMLMNA | |
| SCHEMBL10358621 | 0.82 | MEN1 (0.41) | MEN1KMT2ATSHRPKMLMNA | |
| SCHEMBL4972633 | 0.78 | MME (0.53) | MEN1KMT2ATSHRPKMLMNA | |
| SCHEMBL4908073 | 0.77 | TSHR (0.51) | TSHRLMNAALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL5242531 | 0.75 | MME (0.47) | TSHRALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL5242540 | 0.75 | MME (0.47) | TSHRALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL4968334 | 0.74 | KDM4C (0.54) | MEN1KMT2ATSHRALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1985297-A1 | CARBOXYLIC ACID COMPOUND AND USE THEREOF | Japan Tobacco, Inc. (JP) | 2008-10-29 | — | — | EP | disclosed |
| US-20070197512-A1 | Carboxylic Acid Compounds and Use Thereof | JAPAN TOBACCO INC. (JP) | 2007-08-23 | — | — | US | disclosed |
| EP-0243018-B1 | THIOLACTAM-N-ACETIC ACID DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1990-10-24 | — | — | EP | disclosed |
| US-4771050-A | ALDOSE REDUCTASE INHIBITOR, ANTICOAGULANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-09-13 | — | — | US | disclosed |
| EP-0243018-A1 | Thiolactam-N-acetic acid derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1987-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197512-A1 | Carboxylic Acid Compounds and Use Thereof | GLS, SLC10A1, SOAT1 | MEN1 4288/4885KMT2A 1121/4885TSHR 4003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.